Michael F. Mahoney - Jan 1, 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Jan 1, 2025
Transactions value $
-$2,291,594
Form type
4
Date filed
1/3/2025, 04:32 PM
Previous filing
Nov 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +57.1K +3.75% $0.00 1.58M Jan 1, 2025 Direct F1
transaction BSX Common Stock Tax liability -$2.29M -25.7K -1.63% $89.32 1.55M Jan 1, 2025 Direct
holding BSX Common Stock 201K Jan 1, 2025 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Options Exercise $0 -57.1K -100% $0.00 0 Jan 1, 2025 Common Stock 57.1K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
F2 Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.